Kelly Shi
Stock Analyst at Jefferies
(1.76)
# 2,110
Out of 4,667 analysts
25
Total ratings
32%
Success rate
-7.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelly Shi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $13 → $19 | $16.74 | +13.50% | 2 | Sep 11, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $18 | $7.86 | +129.01% | 1 | Sep 3, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $174 → $196 | $124.38 | +57.58% | 2 | Aug 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | $21 | $10.96 | +91.61% | 1 | Aug 13, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $37 | $15.95 | +131.97% | 1 | Jun 28, 2024 | |
| PROK ProKidney | Maintains: Buy | $15 → $6 | $1.65 | +263.64% | 2 | Jun 10, 2024 | |
| PTCT PTC Therapeutics | Maintains: Buy | $35 → $46 | $41.96 | +9.63% | 3 | May 20, 2024 | |
| TIL Instil Bio | Downgrades: Hold | $5 → $11 | $23.36 | -52.91% | 1 | Apr 12, 2024 | |
| INCY Incyte | Initiates: Buy | $81 | $71.05 | +14.00% | 1 | Feb 23, 2024 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $35 | $27.41 | +27.69% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $2.26 | +1,492.92% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $287 | $194.26 | +47.74% | 1 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $49.82 | -67.88% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $44.05 | -9.19% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $8.36 | +139.23% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.88 | +64.10% | 1 | Aug 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $0.97 | +2,691.85% | 1 | Mar 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $52 | $17.96 | +189.53% | 1 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.05 | +2,471.43% | 1 | Apr 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $2.09 | +1,478.95% | 1 | Mar 8, 2021 |
Centessa Pharmaceuticals
Sep 11, 2024
Maintains: Buy
Price Target: $13 → $19
Current: $16.74
Upside: +13.50%
Foghorn Therapeutics
Sep 3, 2024
Initiates: Buy
Price Target: $18
Current: $7.86
Upside: +129.01%
Ascendis Pharma
Aug 13, 2024
Maintains: Buy
Price Target: $174 → $196
Current: $124.38
Upside: +57.58%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: $21
Current: $10.96
Upside: +91.61%
Syndax Pharmaceuticals
Jun 28, 2024
Initiates: Buy
Price Target: $37
Current: $15.95
Upside: +131.97%
ProKidney
Jun 10, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.65
Upside: +263.64%
PTC Therapeutics
May 20, 2024
Maintains: Buy
Price Target: $35 → $46
Current: $41.96
Upside: +9.63%
Instil Bio
Apr 12, 2024
Downgrades: Hold
Price Target: $5 → $11
Current: $23.36
Upside: -52.91%
Incyte
Feb 23, 2024
Initiates: Buy
Price Target: $81
Current: $71.05
Upside: +14.00%
ArriVent BioPharma
Feb 20, 2024
Initiates: Buy
Price Target: $35
Current: $27.41
Upside: +27.69%
Feb 5, 2024
Initiates: Buy
Price Target: $36
Current: $2.26
Upside: +1,492.92%
Aug 17, 2023
Initiates: Buy
Price Target: $287
Current: $194.26
Upside: +47.74%
Nov 11, 2022
Initiates: Buy
Price Target: $16
Current: $49.82
Upside: -67.88%
Aug 15, 2022
Initiates: Buy
Price Target: $40
Current: $44.05
Upside: -9.19%
Aug 15, 2022
Initiates: Buy
Price Target: $20
Current: $8.36
Upside: +139.23%
Aug 3, 2022
Initiates: Buy
Price Target: $8
Current: $4.88
Upside: +64.10%
Mar 4, 2022
Initiates: Buy
Price Target: $27
Current: $0.97
Upside: +2,691.85%
Aug 3, 2021
Initiates: Buy
Price Target: $52
Current: $17.96
Upside: +189.53%
Apr 13, 2021
Initiates: Buy
Price Target: $27
Current: $1.05
Upside: +2,471.43%
Mar 8, 2021
Initiates: Buy
Price Target: $33
Current: $2.09
Upside: +1,478.95%